Recognition and treatment of endotoxemia

Endotoxemia occurs secondary to several diseases that disrupt the mucosal barrier to bacteria or their toxins. The effects of endotoxemia are varied and are mediated by a wide variety of proinflammatory substances. Although evidence certainly exists to incriminate the cyclooxygenase-derived products of arachidonic acid in the early responses to endotoxemia, various other mediators must also be considered. Treatment presently involves fluid replacement, correction of acid-base abnormalities, augmentation of cardiovascular function, and inhibition of cyclooxygenase activity.     

Anthelmintic resistance in New Zealand: A perspective on recent findings and options for the future

A recent national survey on anthelmintic resistance in cattle and sheep in New Zealand indicated that the magnitude of the problem has increased from very low levels only a few years ago to disturbingly high levels now. There is a particular problem with multiple resistance to all three action families of anthelmintic currently available in Ostertagia (= Teladorsagia) spp in sheep, and to both macrocyclic lactones (ML) and benzimidazoles in Cooperia spp in cattle. The prevalence and extent of resistance indicate that all cattle farmers and most sheep farmers should now be using a combination anthelmintic on most occasions just to achieve effective control of all parasites. Despite this, the presence of resistant parasites has generally not been appreciated by the majority of affected farmers, possibly because most have not formally tested to determine the resistance status of nematodes on their farms.

Anthelmintics will remain the cornerstone of gastrointestinal nematode control in sheep and cattle for the foreseeable future but to ensure their continued effectiveness farmers need to be constantly aware of the need to maintain adequate reservoirs of unselected nematodes, i.e. worms in refugia, to minimise the expansion of the resistant population. High-risk practices in relation to selection of resistance need to be identified and avoided or at least their use limited. These include: treating adult animals where there is no identified need, moving newly- treated animals onto ‘clean’ pasture, and failing to effectively quarantine-drench bought-in animals. None of these are new concepts but many have not been adopted or practised. In particular, sheep farmers should endeavour to avoid treating ewes pre-lambing with long-acting anthelmintics. Farmers needs to negotiate a balance between achieving good parasite control and the sustainability of their control options.     

Anthelmintic resistance in New Zealand: a perspective on recent findings and options for the future

A recent national survey on anthelmintic resistance in cattle and sheep in New Zealand indicated that the magnitude of the problem has increased from very low levels only a few years ago to disturbingly high levels now. There is a particular problem with multiple resistance to all three action families of anthelmintic currently available in Ostertagia (= Teladorsagia) spp in sheep, and to both macrocyclic lactones (ML) and benzimidazoles in Cooperia spp in cattle. The prevalence and extent of resistance indicate that all cattle farmers and most sheep farmers should now be using a combination anthelmintic on most occasions just to achieve effective control of all parasites. Despite this, the presence of resistant parasites has generally not been appreciated by the majority of affected farmers, possibly because most have not formally tested to determine the resistance status of nematodes on their farms. Anthelmintics will remain the cornerstone of gastrointestinal nematode control in sheep and cattle for the foreseeable future but to ensure their continued effectiveness farmers need to be constantly aware of the need to maintain adequate reservoirs of unselected nematodes, i.e. worms in refugia, to minimise the expansion of the resistant population. High-risk practices in relation to selection of resistance need to be identified and avoided or at least their use limited. These include: treating adult animals where there is no identified need, moving newly treated animals onto 'clean' pasture, and failing to effectively quarantine-drench bought-in animals. None of these are new concepts but many have not been adopted or practised. In particular, sheep farmers should endeavour to avoid treating ewes pre-lambing with long-acting anthelmintics. Farmers needs to negotiate a balance between achieving good parasite control and the sustainability of their control options.     

Current status and future perspectives for sequencing livestock genomes

Only in recent years, the draft sequences for several agricultural animals have been assembled. Assembling an individual animal’s entire genome sequence or specific region(s) of interest is increasingly important for agricultural researchers to perform genetic comparisons between animals with different performance. We review the current status for several sequenced agricultural species and suggest that next generation sequencing (NGS) technology with decreased sequencing cost and increased speed of sequencing can benefit agricultural researchers. By taking advantage of advanced NGS technologies, genes and chromosomal regions that are more labile to the influence of environmental factors could be pinpointed. A more long term goal would be addressing the question of how animals respond at the molecular and cellular levels to different environmental models (e.g. nutrition). Upon revealing important genes and gene-environment interactions, the rate of genetic improvement can also be accelerated. It is clear that NGS technologies will be able to assist animal scientists to efficiently raise animals and to better prevent infectious diseases so that overall costs of animal production can be decreased.     

Achievements and future perspectives of embryo transfer technology in pigs

Commercial embryo transfer (ET) has unprecedented productive and economic implications for the pig sector. However, pig ET has been considered utopian for decades mainly because of the requirements of surgical techniques for embryo collection and embryo deposition into recipients, alongside challenges to preserve embryos. This situation has drastically changed in the last decade since the current technology allows non‐surgical ET and short‐ and long‐term embryo preservation. Here, we provide a brief review of the improvements in porcine ET achieved by our laboratory in the past 20 years. This review includes several aspects of non‐surgical ET technology and different issues affecting ET programmes and embryo preservation systems. The future perspectives of ET technology are also considered. We will refer only to embryos produced in vivo since they are the only type of embryos with possible short‐term use in pig production.     

Spinal cord injury in small animals 2. Current and future options for therapy.

Although there can be substantial spontaneous improvements in functional status after a spinal cord injury, therapeutic intervention is desirable in many patients to improve the degree of recovery. At present only decompressive surgery and the neuroprotective drug methylprednisolone sodium succinate are effective and in widespread clinical use. There are limitations to the efficacy of these therapies in some clinical cases and they cannot restore satisfactory functional status to all patients. Many drugs have been investigated experimentally to assess their potential to preserve injured tissue and promote functional recovery in clinically relevant settings, and several of them would be suitable for assessment in future veterinary clinical trials. In addition, experimental techniques designed to mould the response of the CNS to injury, by the promotion of axonal regeneration across the lesion and the encouragement of local sprouting of undamaged axons, have recently been successful, suggesting that effective therapy for even very severe spinal cord injury may soon be available.     

Clinical efficacy of tirilazad mesylate for treatment of endotoxemia in neonatal calves.

The clinical efficacy of the lazaroid, tirilazad mesylate, a new therapeutic agent for prophylaxis and treatment of endotoxemia, was evaluated in 24 neonatal Holstein calves. Endotoxemia was induced by IV infusion of commercial Escherichia coli lipopolysaccharide (3.25 micrograms/kg of body weight) over 3 hours. Group-1 calves were given endotoxin alone; group-2 calves were given an infusion of 0.9% sterile saline solution, then were treated with tirilazad mesylate (1.5 mg/kg) 1 hour after the infusion was started. Group-3 calves were treated with tirilazad mesylate 1 hour after the start of the endotoxin infusion, and group-4 calves were given tirilazad mesylate 1 hour before the start of the endotoxin infusion. Clinical signs of endotoxemia were mitigated by tirilazad mesylate. In addition, tirilazad mesylate protected calves from endotoxin-induced hyperglycemia; treatment after endotoxin infusion decreased the severity of hypoglycemia and prevented lactic acidosis. Treatment with tirilazad mesylate after initiation of endotoxin infusion was as protective as was pretreatment.     

传染性喉气管炎的预防有了新方法

要点:①传染性喉气管炎(Infectious Laryngotracheitis,ILT)在美洲地区流行加剧。②ILT重组疫苗也会对马立克氏病产生免疫保护作用。     

Therapeutic options for the treatment of chronic pain in dogs

Chronic pain is a widely recognised problem in humans and is being increasingly recognised as a significant problem in dogs. Whilst a large number of therapies are described and utilised to treat chronic pain in dogs, there is a severe shortage of evidence to guide practitioners in selection of treatments. Until more evidence becomes available, practitioners should adopt a cautious approach, utilising licensed treatments first when possible. Non‐pharmacological therapies should be incorporated into the chronic pain management plan whenever possible. Given the probable prevalence of chronic pain in dogs there is an urgent need for research to identify effective treatments.     

Pharmaceutical and nutraceutical management of canine osteoarthritis: present and future perspectives

Osteoarthritis (OA) is one of the most common chronic musculoskeletal diseases and causes of lameness in the dogs. The osteoarthritic disease process involves the entire synovial joint, encompassing the synovium, cartilage and underlying bone. Joint failure results from an abnormal mechanical strain causing damage to normal tissue or failure of pathologically impaired articular cartilage and bone under the influence of normal physiological strain or a combination of both. In both cases, the end point is cartilage loss and joint impairment. Osteoarthritic chondrocytes show an altered phenotype characterised by an excess production of catabolic factors, including metalloproteinases and reactive oxygen species. These factors constitute potential therapeutic targets and some new drugs and nutraceuticals have been proposed to promote the return to homeostasis. Until now, the therapeutic management of OA in dogs has been dominated by nonsteroidal anti-inflammatory drugs, but some new compounds, including diacerhein, with potential structure-modifying effects, are already used to treat OA in humans and could be helpful to manage OA in the dog. In addition, novel nutraceuticals, such as avocado/soybean unsaponifiable substances, have shown symptomatic effects in knee OA in humans, and could offer an alternative to prevent OA progression. This paper provides an overview of recent discoveries in the pathophysiology and in the therapeutic management of osteoarthritis in dogs.     

Future options for brucellosis surveillance in New Zealand beef herds

It is probable that bovine brucellosis will be eradicated from New Zealand by 1990. However, continued surveillance for the disease will have to be maintained for a number of years. This paper examines alternative methods of surveillance in beef herds with a view to ensuring that the most cost effective method is used. The three surveillance methods examined are the present automated complement fixation test, abattoir surveillance, and a system based on a delayed hypersensitivity skin test using a purified Brucella protein antigen. It is concluded that despite the relatively low sensitivity of the skin test the probability of its identifying herds as infected is likely to be greater in practice than abattoir surveillance. The skin test is cheaper than the present complement fixation test.